focu minim invas therapi address critic need
boston scientif corp agre buy british firm btg plc
bolster presenc grow field
intervent medicin term agreement btg common
sharehold receiv cash consider penc per share
btg gener develop product use
minimally-invas surgic procedur treat vascular diseas
cancer btg three key busi area largest
intervent medicin portfolio product busi includ
theraspher radiotherapi microspher galil cryoablat
system use treat patient liver kidney cancer
btg also vascular portfolio includ filter cross cathet
microfoam eko endovascular system first devic
approv fda treatment pulmonari embol
market valu nearli one
biggest maker heart devic pacemak artery-open stent
 roll year acquir california stent maker
veiniti inc deal worth august juli acquir claret
medic also bought cryterion medic inc
btg focu minim invas treatment today
challeng condit transact would also allow
leverag global presenc util clinic evid
gener capabl increas patient access btg differenti
therapi throughout asia europ latin america
expect repay least borrow within month follow
close transact allow achiev leverag
within two year still maintain financi flexibl invest
growth-ori share repurchas combin busi would
bring great benefit patient around world well bsx
novemb announc reach
agreement term recommend offer acquir btg plc uk
base biotechnolog compani transact unanim approv
board director boston scientif btg plc
term transact holder btg common share would
receiv cash consider penc per share total cash consider
btg equiti transact intend
effect way english court-sanct scheme arrang
expect close subject receipt requir regulatori
approv approv btg sharehold court
btg plc uk base compani develop commerci product
use minimally-invas procedur target cancer vascular diseas
well acut care pharmaceut btg three key busi largest
intervent medicin portfolio encompass sever
includ theraspher radiotherapi microspher galil
cryoablat system use treat patient liver kidney cancer
boston scientif corpor develop manufactur market
medic devic use rang intervent medic specialti
transform live innov medic solut
improv health patient around world
acquisit btg rapidli grow peripher intervent
portfolio excit extens bsx categori leadership strategi
augment capabl import area unmet need cancer
pulmonari embol confid addit therapi
portfolio ultim advanc patient care way could realiz
either compani alon
term transact
board bravo bidco btg announc
reach agreement term recommend cash offer bravo bidco
acquisit entir issu issu ordinari share capit
receiv irrevoc undertak vote favor
transact btg three largest sharehold cover aggreg
btg outstand share well btg director hold
addit btg share transact would fund
combin cash hand proce debt financ enter
full term propos transact includ full term
undertak btg sharehold director set forth
announc made bravo bidco limit wholli own
subsidiari form effect propos transact btg
accord rule citi code takeov merger
enter bridg financ facil provid
receipt commit financ satisfi certain fund
requir take-over code
term acquisit btg sharehold entitl receiv
btg share penc cash offer price offer price
valu entir issu issu ordinari share capit btg
repres premium
close price penc per btg share novemb
last busi day announc
btg trade day volume-weight averag share price
period end novemb last busi day
term transact
btg share acquir acquisit acquir fulli paid
free lien charg equit interest encumbr right pre-
emption right interest natur whatsoev
togeth right hereaft attach thereto
dividend distribut author declar made paid
respect btg share date announc prior
effect date bravo bidco reserv right reduc offer price
amount part dividend distribut
acquisit subject condit certain term set
appendix announc includ amongst thing
approv major number scheme sharehold repres
least valu scheme share present entitl vote vote
either person proxi court meet
approv resolut connect implement
scheme requisit major btg sharehold gener meet
sanction scheme court
scheme becom effect later long stop date
receipt competit clearanc expir termin
wait period applic us hsr act
either decis make phase refer absenc
request submit merger notic indic
initi period begun condit met
receipt merger control clearanc expir termin
wait period applic germani german act
restraint competit spain spanish competit act
altern case referr articl eu merger regul
member state european commiss eu
one largest independ medic technolog
compani world wide rang product offer address
possess long histori growth intern innov complement
select acquisit regularli review opportun divers set
believ acquisit repres compel
opportun build upon strength boston scientif peripher
intervent divis addit btg high growth
btg pharmaceut busi add profit portfolio lifesav acut care
drug licens busi add portfolio profit licens
pharmaceut product gener stream royalti minim
boston scientif comprehens global research develop clinic
commerci expertis combin btg strong posit grow area
intervent oncolog intervent vascular posit
combin entiti better serv patient payor provid around
btg focu minim invas therapi address critic need
expect acquisit deliv short long-term
strengthen offer area cancer treatment
addit btg highli differenti intervent oncolog
segment enabl expand treatment option
advanc categori leadership strategi peripher
intervent segment ad high growth revenu
month period end septemb boston scientif
expand venou portfolio offer ad btg
pulmonari embol franchis addit highli differenti
provid strong return boston scientif investor includ
ad two three cent accret boston scientif adjust
earn per share increas level accret thereaft
deliv signific revenu cost synergi boston
scientif enhanc global manufactur capabl boston
scientif btg combin geograph footprint
expect combin synergi complet
transact expect
third year complet year
confid abil deliv strategi
acquisit demonstr strong track record integr
acquisit organ drive revenu growth
oper improv acquisit past five
continu diversifi portfolio expand higher growth segment
differenti solut high growth intervent oncolog
venou portfolio particular btg acceler strategi
strengthen growth profil pi overal
revenu mix segment growth rate
continu shift higher growth market
btg creat best class portfolio address m/hsd growth
btg uniqu intervent medicin product perfect complement
bsx current pi portfolio provid entri new attract
peripher segment current compet
acquisit btg enabl add radio-embol
uniqu radiopaqu bead well cryo microwav ablat
exist io portfolio coil microcathet guidewir
would acceler full-lin cancer therapi provid
one primarili deliveri tool coil potenti plu
busi multipl new innov therapeut technolog
better serv intervent radiologist custom
add sever adjac product advanc treatment multipl
venou disord eko thrombolysi system demonstr posit
outcom treat pulmonari embol support strong evid
varithena novel treatment varicos vein recent
relaunch dedic code would re-enter
vena cava filter market world first five convert vena cava filter
vena cava filter call sentri support excel two-year
btg theraspher radioact glass microspher deliv high dose
local radiat directli right tumor enabl person
medicin approach high concentr radioact per sphere
believ confer competit advantag strong clinic
evid on-going seri clinic trial posit lead
galil cryoablat microwav ablat system develop
uniqu opportun part palli care also
cur patient suffer cancer
technolog serv differenti platform plan expand
cancer clinic studi product develop process
expand theraspher cryoablat lung cancer lead
caus cancer death also program underway expand indic
breast cancer bone metastas
btg acut specialti pharma licens offer attract profit
btg pharmaceut product use hospit emerg room
intens care unit product typic address condit small
patient popul limit exist treatment
product within pharmaceut portfolio includ crofab anti-
venom snakebit digifab anecdot digoxin toxic
voraxaz anecdot methotrex overdos
crofab use patient sinc fda
approv product deriv exclus snake approv
treat north american pit viper envenom adult pediatr
crofab face newli launch competit product long-establish
safeti efficaci profil enabl remain durabl leader
btg earn royalti product sold license btg licens
busi requir littl support infrastructur quit
profit key primari revenu stream deriv market lead
cancer drug call zytiga zytiga licens johnson johnson use
treatment prostat cancer
believ transact enhanc growth profil creat
signific valu sharehold add high growth
intervent busi acceler categori leadership strategi
intervent oncolog venu
expect realiz revenu cost synergi least million
year potenti meaning revenu synergi pull-through
btg product line bsx market-lead global pi commerci engin
btg headquart london unit kingdom global healthcar compani
focus intervent medicin fast-grow oncolog vascular
portfolio advanc treatment cancer blood clot varicos vein
minim invas procedur
btg cash-gen busi provid life-sav
product treat patient overexpos certain medic toxin
btg form merger uk govern nation
research develop council nation enterpris board sinc
flotat london stock exchang group built
capabl infrastructur support on-going busi growth global
btg signific direct commerci presenc europ us
support group growth geograph expans btg continu
develop product portfolio invest pipelin innov
clinic studi well focus acquisit strategi btg oper
two busi intervent medicin also receiv
royalti legaci licens activ
btg sale increas compar
prior-year period product sale increas
licens revenu increas adjust
profit increas adjust margin
intervent medicin gener sale
oncolog vascular pharmaceut
gener net cash cash equival
septemb
incom statement total gross research sale gener restructur merger oper total oper oper incom incom provis incom net incom avail common weight averag share actual annual corporation| decemb
cash current total current net properti plant intang defer incom prepaid pension long-term total non-curr total account tax current total current defer tax accru minor long-term total non-curr total common addit paid-in retain accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual corporation| decemb
depreci invest loss defer incom stock base chang work work non-cash net cash provid oper invest properti plant properti plant equip reductions- acquisit purchas invest net cash use invest debt common stock financ net cash provid use financ effect exchang rate net chang begin end corporation| decemb
gross margin increas slightli ttm basi compar
oper margin increas ttm basi compar due declin
net margin increas ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corporation| decemb
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale boston scientif corporation| decemb
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset boston scientif corporation| decemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt equity- gross margin oper margin net margin total equiti total lt debt total asset- asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item boston scientif corporation| decemb
outstand equival market debt equity- common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas investment- sale investment- issuanc repurchas stock- net issuanc prefer stock- net issuanc debt- dividends- net chang capit free corporation| decemb
ytd perform
stock vs
roa roi roe
ttm
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corporation| decemb
consensu view analyst trend stock
forward price-to-earnings multipl
btg compar
 average
price-to-book ratio
btg compar
industri average
annual gbpgrowth high day day day estim avgfive-year growth forecast comparisonbtggfindustri avg avgprice/earn yield corporation| decemb
btg stock price surg announc acquisit novemb stock fell
nearli januari mid-juli one lead devic lung coil emphysema struggl
secur regulatori approv howev stock gave return last one year rang
stock
whole lot acquisit enhanc long-term growth profil
maintain buy rate upgrad tp
previous estim tp
base forward price-to-earnings multipl adjust
ep provid upsid potenti
estim base follow factor strong
growth across segment acquisit made
period new product launch
deliv strong perform quarter
y/i revenu growth adjust ep
growth y/i continu
gener y/i increas adjust free cash flow
quarter
oper sale increas asia-pacif
 europe/mideast africa latin
america/canada emerg market sale grew
oper led strong perform china latin
busi region continu grow faster
market medsurg led way growth
rhythm neuro grew cardiovascular sale
increas organ basi
endoscopi revenu grew y/i report
quarter due momentum core endo busi
endochoic sale patholog infect prevent
franchis endoscopi well posit
launch new product includ spyglass ds ii orca
hemostasi pod infect prevent oris gel
compani name tickerbsxstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corporation| decemb
urolog pelvic health revenu increas y/i
report quarter growth led mid-
teen growth stone franchis growth lithovu
ureteroscop well high single-digit growth men
prostat health grew high-singl digit intern
expans greenlight laser therapi continu
adopt rezum minim invas therapi bph
acquisit augmenix further categori leadership
strategi spaceoar hydrogel ad grow
neuromodul sale grew quarter due
on-going success launch innov wavewrit
spinal cord system increas demand
europ prepar launch recharg
primari cell db system direct lead
end
peripher intervent revenu grew
quarter due strong growth across geographi
franchis launch eluvia
receiv outstand result imperi trial
show superior eluvia first head-to-head
studi kind eluvia signific market opportun
near futur
recommend buy rate tp
growth revenu strong portfolio
busi due recent acquisit captur share
emerg market launch new product
plan launch futur well contribut
growth busi
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date inform boston scientif corporation| decemb
non- reconcili refer page
incom statement item total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli corporation| decemb
cash defer incom prepaid current total current net properti plant intang long-term total non-curr total short-term account accru current total current long-term capit defer tax accru long-term total non-curr total common addit paid-in retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli corporation| decemb
provid oper activ period compar
decreas due payment ir tax settlement
use invest activ period compar
cash use invest activ includ payment acquisit busi
purchas properti plant equip payment relat invest acquisit
provid financ activ increas period compar
flow provid financ activ reflect issuanc repay debt
along cash use net share settl employe equiti award stock issuanc relat equiti
statement depreci amort debt discount/premium issuanc investment/asset impair invest loss defer incom stock base chang work account work non-cash net cash provid oper invest properti plant properti plant equip acquisit purchas sales/matur invest net cash use invest debt debt common stock common stock financ net cash provid use financ effect exchang rate net chang begin end boston scientif corporation| decemb
report strong quarterli result due acquisit
nxthera inc claret medic inc
report
basi
compar
total revenu increas report basi
compar total revenu increas
oper basi organ basi increas includ
oper net sale due acquisit nxthera
inc claret medic inc
total revenu increas compar
revenu emea europ middl east
africa increas compar
revenu apac asia-pacif increas
compar revenu latin america canada
increas compar
revenu emerg market increas
compar
revenu emea
europ middl east
africa increas
compar
cog increas compar
gross profit increas compar
increas
compar
gross margin increas compar
increas due favor period expens compar
prior-year well posit impact cost reduct result
process improv program restructur program partial off-set
neg impact foreign currenc fluctuat
sg expens increas compar
sg sale increas
compar
 expens increas compar
 sale compar
 expens increas result invest
across busi order maintain healthi pipelin new product
compar
ep
compar
royalti expens compar
amort expens compar
interest expens compar
effect tax rate compar
net incom increas compar
adjust net incom
ep increas compar
adjust ep compar
increas
compar
period net incom
increas
compar
period total revenu increas
compar period cog
increas compar
period gross profit increas
compar period gross
margin compar
period sg expens increas
compar sg expens sale
compar decreas sg expens
due benefit target initi focus reduc sg
expens includ end-to-end busi process streamlin autom
expans global share servic leverag global sourc
period expens increas
compar period
expens sale compar
period royalti expens
compar period amort
expens compar
interest expens compar
period effect tax rate
compar chang tax rate relat impact
certain receipt charg tax differ rate effect
tax rate receipt charg includ intang asset impair
well certain discret tax item
period net incom increas
compar period
gaap ep increas compar
three report segment compris cardiovascular
rhythm manag medsurg repres aggreg
oper segment creat new segment rhythm neuro segment
includ cardiac rhythm manag electrophysiolog
neuromodul previous includ medsurg segment
total revenu
increas
compar
total revenu
increas
compar
total revenu cardiovascular segment increas
compar
period total revenu increas
compar
oper incom increas compar
oper margin compar
cardiovascular segment repres total
sale
total revenu intervent cardiolog busi increas
compar
period total revenu increas
compar
cardiovascular neuro total revenu
increas
compar
total revenu
increas
compar
total revenu increas
compar total intern revenu increas
compar
increas due structur heart therapi includ
transcathet aortic valv replac tavr platform sentinel
cerebr embol protect system purchas part claret
acquisit sale complex percutan coronari
intervent pci product offer also contribut growth
partial off-set declin drug-elut coronari stent de sale
total revenu peripher intervent increas
compar
period total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
increas due strong perform region particularli
asia latin america growth intervent oncolog product
balloon eluvia drug elut vascular stent system core
technolog treat vascular diseas
total revenu medsurg segment increas
compar
period total revenu increas compar
oper incom increas compar
oper margin
compar medsurg repres total sale
urolog pelvic health
total revenu urolog pelvic health busi increas
compar
period total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
increas attribut growth sale kidney stone product
includ lithovu digit flexibl ureteroscop men health
product bph busi includ rezm system purchas
part nxthera acquisit
total revenu endoscopi busi increas
compar
period total revenu increas compar
total revenu increas
compar total intern revenu increas
compar
increas due growth hemostasi franchis featur
resolut clip biliari franchis spyglass ds direct
visual acquir endoscop ultrasound fine needl
biopsi devic infect prevent product patholog servic
total revenu
urolog pelvic health
busi increas
compar
total revenu
increas
compar
rhythm neuro
total revenu rhythm neuro segment increas
compar
period total revenu increas
compar
oper incom increas compar
oper margin
compar rhythm neuro segment repres
total sale
total revenu electrophysiolog busi increas
compar
period total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
total revenu neuromodul busi increas
compar
period total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
increas due launch spectra wavewrit spinal cord
stimul system first fda approv system
simultan provid paresthesia-bas sub-percept therapi
increas intern sale
total revenu
rhythm neuro
segment increas
compar
total revenu
busi increas
compar
rhythm neuro
total revenu cardiac rhythm manag increas
compar
period total revenu increas
compar
total revenu increas
compar total intern revenu decreas
compar
increas due strong growth across defibril portfolio
due build momentum commerci global reson
hf diagnost favor impact magnet reson imag
mri safe condit label current gener defibril
launch continu market penetr emblem
total revenu
compar
receiv fda approv eluvia drug-elut vascular
stent system follow releas posit data
imperi trial first head-to-head drug-elut stent de trial
obstruct diseas superfici femor arteri patient treat
eluvia stent experienc superior clinic outcom compar
treat zilver ptx cook medic
submit pre-market approv pma applic lotu
edg aortic valv includ file final technic
began enrol saval trial studi saval
knee btk drug-elut stent system design fda
breakthrough devic protocol first stent design treat critic
receiv fda approv promu elit everolimus-elut
platinum chromium coronari stent system enhanc perman
polym de pp-de therapi offer physician choos pp-de
treatment option patient
receiv fda approv visionist cardiac
resynchron therapi pacemak crt-p relianc
defibril lead product also receiv mr-condit
label part rhythm manag imagereadi mr-
condit system portfolio offer approv avail
high low-voltag devic categori
receiv determin district court dusseldorf germani
edward lifesci corpor sapien ultra devic infring
patent establish symeti sa subsidiari court
rule preliminari injunct proceed
right enjoin edward german subsidiari offer sell
sapien ultra germani
submit
pma applic
valv
includ file
approv
crt-p relianc
lead
present two-year ewolut real world registri data
watchman left atrial appendag closur laac devic late-break
clinic trial data demonstr watchman devic continu
safe effect altern long-term warfarin therapi offer
compar stroke risk reduct significantli reduc risk major
bleed patient non-valvular atrial fibril af
complet enrol pinnacl flx prospect multi-cent
clinic trial watchman flx laac devic newest gener
laac devic design treat wider rang patient anatomi increas
eas use improv seal heal within left atrial appendag
launch lithovu empow retriev deploy devic
design enabl individu urologist remov kidney stone via
flexibl ureteroscopi ur simultan control ureteroscop
nitinol retriev basket without second clinician
launch guid xt visual deep brain
stimul db europ guid xt first db
visual system built direction util patient specif
anatomi stimul field model technolog provid physician
imag plan capabl use conjunct
vercis db system enabl physician person optim db
close acquisit claret medic inc privately-held compani
develop commerci sentinel cerebr embol
protect use protect brain certain
intervent procedur predomin patient undergo
technolog add-on payment design sentinel system
 center medicar medicaid servic
close acquisit veniti inc privately-held compani
develop commerci venou stent
enrol pinnacl
flx prospect
watchman flx
launch
guid xt
visual deep
europ
close acquisit augmenix inc privately-held compani
develop commerci spaceoar system therapi use
reduc common debilit side effect men may experi
receiv prostat cancer radiotherapi
announc reach agreement term
recommend offer acquir btg plc compani headquart
unit kingdom develop commerci product use
minimally-invas procedur target cancer vascular diseas well
acut care pharmaceut btg employe global locat
north america europ asia australia
transact unanim approv board director
btg term transact holder btg
common share would receiv cash consider penc per share
total cash consider btg equiti
transact expect close
btg three key busi largest intervent
medicin portfolio encompass sever peripher intervent
product line intervent oncolog franchis includ theraspher
radiotherapi microspher galil cryoablat system use
treat patient liver kidney cancer
btg intervent medicin busi also highly-differenti vascular
portfolio includ filter cross cathet microfoam eko
acquisit btg rapidli grow peripher intervent
portfolio excit extens bsx leadership strategi
augment capabl import area unmet need cancer
acquisit btg
rapidli grow
portfolio excit
extens bsx
leadership strategi
augment
capabl import
area unmet need
cancer
coronari launch complex pcistructur heartacur valv ou expansionperipher interventionseluviatm sfa de reson crt-d heartlog hf alertdirectsens rx cathet eurhythmia hdx map w/ lumipoint softwarespectra wavewrit vercis db system new launch infect prevent valv kit spyglass ds ii visual cholangioscopi toolsaxio translumin stent ou expansionoris endolumin surgeri portfoliourology/pelv launch stonecrm/epneuromodulationendoscopi corporation| decemb
targetbusinessdescriptionclos datetarget commerciallaunchinvestmentmilliped structur hearttmvr full annuloplasti ring mitral ablat gi managementesophag temp pelvic healthminim invas therapi pelvic healthpotenti platform earlierdiagnosi ovarian managementsingl shot therapi -pulmonari vein structur heartembol protect tavr interventionsperipher venou pelvic healthorgan protect prostatecanc radiat expect
revenu
grow rang
adjust ep expect
ep
expect rang
fx impact revenu
adjust sg sale
adjust sale
fx impact ep
tailwind
expect revenu grow
rang
adjust ep expect ep
expect rang
expect revenu grow
rang
adjust ep expect ep
expect rang
deliv strong perform quarter growth
revenu due recent acquisit nxthera claret
adjust ep increas y/i quarter
medsurg led way growth rhythm neuro grew
cardiovascular sale increas organ basi endoscopi well
posit launch new product includ spyglass ds ii orca
hemostasi pod infect prevent oris gel endolumin surgeri
urolog pelvic health revenu increas y/i report
quarter growth led mid-teen growth stone franchis growth
lithovu ureteroscop well high singl digit growth men
structur heart program continu build strong momentum expect
revenu watchman left atrial appendag closur
acur tavr program small contribut recent close
claret develop fentanyl cerebr embol protect system
approv europ protect patient risk stroke
tavi see signific opportun embol protect tavi
launch acur countri continu see strong physician
uptak valv prepar target lotu edg launch
europ
watchman deliv excel growth quarter platform
continu build strong physician support global posit
complet enrol nextgen watchman flx well
ahead schedul continu target eu launch flx japan
remain track watchman launch
acquisit emcis securu nxthera nvision claret cryterion
veniti augmenix target high-growth market enhanc categori
leadership strategi leverag exist bsc global capabl
enhanc short-term long-term growth profil
perform
quarter
growth revenu
due
recent acquisit
nxthera claret
countri
continu see strong
physician uptak
valv prepar
target lotu edg
launch
europ
non- reconcili
non- reconcili
non- reconcili
revenu growth ttm compar
gross margin ttm compar
net margin increas ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corporation| decemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale boston scientif corporation| decemb
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset boston scientif corporation| decemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item boston scientif corporation| decemb
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc repurchas net issuanc prefer stock- net issuanc debt- dividends- net chang capit free corporation| decemb
current price-to-earnings price-to-earnings volatil past due
strong growth stock price compar ep averag price-to-earnings
expect forward price-to-earnings
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluefmr capit world vanguard group inc wellington manag compani primecap manag jp morgan bollard group top mutual fund holdersholdersharesd report outvaluevanguard specialized-health fundament investor growth fund america vanguard total stock market vanguard/primecap vanguard new perspect fund fidel select portfolio medic technolog devic fidel contrafund spdr etf corporation| decemb
develop announc recommend offer acquir btg plc novemb announc reach agreement term recommend offer acquir btg plc compani headquart theunit kingdom develop commerci product use minimally-invas procedur target cancer vascular diseas well acut care pharmaceut term transact holder btg common share would receiv cash consider penc per share total cash consider btg equiti approxim prevail german edward lifesci litigationoctob corpor announc district court ofdusseldorf germanyha determin edward lifesci corpor sapien ultra devic infring patent establish symeti sa subsidiari specif fabric use valv seal specif german part european patent ep thedusseldorfcourt rule preliminari injunct proceed right enjoin edward german subsidiari offer sell sapien ultra ingermani infring injunct decis appeal edward edward currently-avail sapien devic found infring two patent ep ep court rule appeal edward enabl enjoin sapien german market compani yet exercis option solyx single-incis sling demonstr treatment success meet endpoint three-year studi women stress urinari incontinenceoctob corpor announc solyx singl incis sling si achiev treatment success meet primari secondari endpoint three-year studi women stress urinari incontin trial also demonstr solyx si non-inferior gold-standard transobtur mid-urethr sling procedur long-term success treatment patient launch lithovu empow retriev deploy deviceseptemb corpor announc global launch lithovu empow retriev deploy devic design use lithovu single-us digit flexibl ureteroscop compat nitinol retriev basket enabl urologist oper ureteroscop basket simultan retriev kidney stone via flexibl ureteroscopi ur lithovu empow devic one sever new devic plan address unmet need ineffici stone procedur innov corporation| decemb
higher
compar
sale growth rate
ttm compar
industri
gross margin
ttm industri
average
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corporation| decemb
consensu view analyst trend stock
forecast
higher
compar
forward price-to-earnings
higher
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonbsxindustri avg avgprice/earn yield corporation| decemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr corporation| decemb
stock volatil quarter surg octob
stock dip novemb announc btg acquisit
stock gave return quarter averag volum share trade
stock price show upward trend past one-year gave return past
rang stock
stock volatil till saw upward trend past
stock gave return past expand portfolio variou acquisit
expans emerg market
deliv strong quarterli result due strong growth segment due recent acquisit
recommend buy rate base perform period newli
launch product estim tp base forward price-to-earnings multipl
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
